Présentation

Sujets de recherche

Cell Signaling and Cancer, Cell Signaling and Cancer, Cell Therapy of Cancer.

Disciplines de recherche

Cell Biology, Oncology.

Mots-clés

apoptosis, cell signaling, cytokines/death receptors, infectious diseases, microbiology, ovarian cancer, tumor microenvironment.

Intérêts de recherche

My laboratory is working on the apoptotic pathways and how members of the Bcl-2 family of protein may affect their regulation. Alterations of the apoptotic cascade may lead to the development of resistance to chemotherapy as well as new agents that induce apoptosis. These studies are thus essential to provide a better understanding of how tumor cells may develop resistance.

Recherche clinique

Oui

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

• (2004) Best paper award for 2003 in Cytotherapy. (Distinction).

Publications

Articles de revue

• Matte I, Lane D, Bachvarov D, Rancourt C, Piché A. (2104). Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer, 14(258), (Published).
• Piché A. (2015). Pathobiological role of MUC16 mucin (CA125) in ovarian cancer: Much more than a tumor biomarker. World Journal of Obsetrics and Gynecology, (Accepted).
• The Cancer Genome Atlas Research Network. (2015). The molecular taxonomy of primary prostate cancer. Cell, 163, 1011-1025. (Published).
• Matte I Lane D Laplante C Garge-Granger P Rancourt C Piché A. (2015). Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dépendent and -indpendent mechanisms. International Journal of Cancer, 137(2), 289-298. (Published).
• Lane D Matte I Garde-Granger P Laplante C Carignan A Rancourt C Piché A. (2015). Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer, 15, 492.
• Giannakouros P Comamala M Matte I Rancourt C Piché A. (2015). MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering B-catenin signaling. American Journal of cancer research, 5(1), 219-230. (Published).
• Panagiota Giannakouros, Marina Comamala, Isabelle Matte, Claudine Rancourt, and Alain Piché. (2015). MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling. American Journal of Cancer Research, 5(1), 219-230. (Submitted).
• Giannakouros P Matte I Rancourt C Piché A. (2015). Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail. International Journal of Oncology, 46(1), 91-98. (Published).
• Giannakouros P, Matte I, Rancourt C, Piché A. (2015). Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail. Gynecologic Oncology, 46(1), 91-98. (Submitted).
• Matte I, Lane D, Boivin M, Rancourt C, Piché A. (2014). MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer, 14, 234. (Published).
• Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A. (2014). Ovarian cancer ascites enhance the migration of human peritoneal mesothelial cells via cMet-ERK1/2-Akt pathways. International Journal of Cancer, (In Press).
• Rodrigues-Coutlée C , Archambault J , Money D , Ramanakumar AV , Raboud J , Hankins C , Koushik A , Richardson H , Brassard P , Franco EL , Coutlée F ,. (2013). Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 58(4),
• Le Page C, Kobel M, de Ladurantaye M, Rahimi K, Madore J, Babinzky S, Bachvarov DR, Bachvarova M, Beauchamp MC,Cass CE, Chardwick D, Colleen C, Damaraju S, DufourJ, Gotlieb W, Kalloger SE, Portelance L, McAlpinne JN, Matte I, Piché A, Shaw P, Vandehyden B, Watson P, Huntsman DG, Provencher DM, Mes-Masson AM. (2013). Specimen quality evaluation in Canadian biobanks participating in the COEUR reposiitory. Biopreservation and Biobanking, 11(2), 83-93. (Published).
• Bjerk SM , Baker JV , Emery S , Neuhaus J , Angus B , Gordin FM , Pett SL , Stephan C , Kunisaki KM , SMART group (including Piche A). (2013). Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PloS one, 8(2),
• Lane D , Matte I , Laplante C , Garde-Granger P , Rancourt C , Piché A. (2013). Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. Journal of ovarian research, 6(1),
• Zetterberg E , Neuhaus J , Baker JV , Somboonwit C , Llibre JM , Palfreeman A , Chini M , Lundgren JD , SMART group (including Piche A). (2013). Platelet count kinetics following interruption of antiretroviral treatment. AIDS (London, England), 27(1),
• Lane D , Matte I , Rancourt C , Piché A. (2012). Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. Journal of ovarian research, 5(1),
• Goncharenko-Khaider N , Matte I , Lane D , Rancourt C , Piché A. (2012). Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Molecular cancer, 11,
• Matte I , Lane D , Laplante C , Rancourt C , Piché A. (2012). Profiling of cytokines in human epithelial ovarian cancer ascites. American journal of cancer research, 2(5),
• Khaider NG , Lane D , Matte I , Rancourt C , Piché A. (2012). Targeted ovarian cancer treatment: the TRAILs of resistance. American journal of cancer research, 2(1),
• Thériault C , Pinard M , Comamala M , Migneault M , Beaudin J , Matte I , Boivin M , Piché A , Rancourt C. (2011). MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecologic oncology, 121(3),
• Pett SL , Carey C , Lin E , Wentworth D , Lazovski J , Miró JM , Gordin F , Angus B , Rodriguez-Barradas M , Rubio R , Tambussi G , Cooper DA , Emery S , ESPRIT group (including Piché A). (2011). Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV medicine, 12(4),
• Comamala M , Pinard M , Thériault C , Matte I , Albert A , Boivin M , Beaudin J , Piché A , Rancourt C. (2011). Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. British journal of cancer, 104(6),
• Lane D , Matte I , Rancourt C , Piché A. (2011). Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC cancer, 11,
• Holodniy M , Brown ST , Cameron DW , Kyriakides TC , Angus B , Babiker A , Singer J , Owens DK , Anis A , Goodall R , Hudson F , Piaseczny M , Russo J , Schechter M , Deyton L , Darbyshire J , OPTIMA group (including Piché A). (2011). Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. PloS one, 6(3),

Chapitres de livre

• Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A. (2013). Biological significance of apoptosis in ovarian cancer : TRAIL therapeutic targeting. Ovarian cancer: a clinical and translation update INTECH. (Published).
• Rancourt C, Matte I, Lane D, Piché A. (2012). The role of MUC16 mucin (CA125) in the pathogenesis of ovarian cancer. Ovarian Cancer: Basic science perspective INTECH. (Published).

Lignes directrices en matière de soins cliniques

• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2013). La pharmacométrie clinique des antirétroviraux et l'individualisation de la thérapie antirétrovirale chez les adultes et les enfants vivant avec le VIH.
• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2013). L'examen médical périodique de l'adulte vivant avec le virus de l'immunodéficience humaine (VIH) - Guide pour les professionnels de la santé du Québec.
• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2013). L'examen médical périodique de l'adulte vivant avec le virus de l'immunodéficience humaine (VIH) - Outil pratique pour les professionnels de la santé du Québec.
• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2012). Les tests de détermination du tropisme viral du VIH-1 - Guide pour les professionnels de la santé du Québec.
• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2011). Guide pour la prophylaxie postexposition (PPE) à des liquides biologiques dans le contexte du travail Octobre 2011.
• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2011). La prise en charge et le traitement des personnes co-infectées par les virus de l'immunodéficience humaine (VIH) et de l’hépatite B (VHB) - Guide pour les professionnels de la santé du Québec.
• Baril JM, Côté P, Junod P, Lalonde R, Lapointe N, Lessard B, Monteith K, Piché A, Rouleau D, Therrien r, Tremblay C, Trottier B, Trottier S, Tsarevsky I, Tsoukas C. (2011). La prise en charge et le traitement des personnes co-infectées par les virus de l’immunodéficience humaine (VIH) et de l’hépatite B (VHB) - Guide pour les professionnels de la santé du Québec (Résumé.

Articles de conférence

• Matte I, Lane D, Laplante C, Rancour C, Piché A. (2012). Cytokine profiling of human epithelial ovarian cancer ascites. 6th conference on ovarian cancer research. (Published).
• Piché A, Matte I, Rancourt C, Bachvarov D. (2012). Gene expression profiling of human mesothelial cells after ovarian cancer ascites treatment. 6th canadian conference on ovarian cancer research. (Published).
• Giannakouros P, Matte I, Rancourt C, Piché A. (2012). Interaction of MUC16 (CA125) with B-catenin. 6th canadian conference on ovarian cancer research. (Published).
• Lane D, Matte I, Rancourt C, Piché A. (2012). Osteoprotegerin (OPG) contributes to cell survival in ovarian cancer. 6th canadian conference on ovarian cancer research. (Published).
• Goncharenko-Khaider N, Lane D, Rancourt C, Piché A. (2012). Ovarian cancer ascites increase Mcl-1 expression through the ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. 6th canadian conference on ovarian cancer research. (Published).
• G. McKercher, A. Aprikian, S. Chevalier, F. Saad, L. Lacombe, M. Carmel, A. Bergeron, A-M. Mes-Masson, A. Piché, B. Têtu, A. Doueik, F. Brimo, M. Latour. (2010). COLLECTIVE EFFORTS TO ESTABLISH A HIGH QUALITY PROSTATE CANCER BIOBANK IN QUÉBEC. Cambridge Healthtech Institute’s Biobanking meeting. (Published).

Autres contributions

Présentations

• (2012). Le cancer de l'ovaire.. où en est la recherche. Café scientifique des IRSC. Sherbrooke.
• (2012). Ovarian cancer ascites increase Mcl-1 expression through the ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. 6th conference on ovarian cancer research. Québec.